Imagen de Portada

Correspondence: Dupilumab‐Induced Blood Eosinophilia—Why We Need to Look Beyond the Blood

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Matteo Gelardi, Rossana Giancaspro, Michele Cassano
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Allergy
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dupilumab and Blood Eosinophilia: A Disease‐Specific Phenomenon?
por: Andrea Portacci, et al.
Publicado: (2025)

Psychological Impact of Biologic Therapy in CRSwNP: A Pilot Study
por: Alessandro Maselli del Giudice, et al.
Publicado: (2025)

Interleukin‐22 and Interleukin‐18 as Potential Blood Biomarkers in Dupilumab‐Treated Atopic Dermatitis
por: Ayano Fukushima‐Nomura, et al.
Publicado: (2026)

Deciphering Immune Endotypes Within Drug Reaction With Eosinophilia and Systemic Symptoms ( DRESS ) Syndrome
por: Camilla von Wachter, et al.
Publicado: (2025)

Point‐of‐Care Blood Eosinophils to Predict Preschool Wheeze Attacks
por: Kushalinii Hillson, et al.
Publicado: (2025)

Correspondence: Proposed amendment to the nomenclature of allergic diseases and hypersensitivity reactions: Looking beyond the classic paradigms
por: Lucyna Mastalerz
Publicado: (2024)

Eosinophilia, atopic dermatitis, and dupilumab: A potentially dangerous liaison?
por: Yung‐Yi Lan, et al.
Publicado: (2026)

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma
por: Michael E. Wechsler, et al.
Publicado: (2026)

Blood basophils and asthma among participants from CONSTANCES, the French population‐based cohort
por: Rachel Nadif, et al.
Publicado: (2024)

Correspondence: Anaphylaxis Induced by Goat's and Sheep's Milk—A Rare Entity in Europe
por: Ewa Cichocka‐Jarosz, et al.
Publicado: (2025)

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
por: Emma J. Anisman, et al.
Publicado: (2026)

Atopic Dermatitis ( AD ) Related Cord Blood DNA Methylation Patterns Are Linked to Maternal AD
por: Laura Matzner, et al.
Publicado: (2025)

Pre‐Analytical Stability of Diagnostic Biomarkers in Primary Blood Tubes for Supporting Remote Allergy Care
por: Janneke Ruinemans‐Koerts, et al.
Publicado: (2025)

Reply to Correspondence: “Anaphylaxis Induced by Goat's and Sheep's Milk—A Rare Entity in Europe”
por: Guillaume Pouessel, et al.
Publicado: (2025)

Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry
por: Stéphanie Wanin, et al.
Publicado: (2025)

Dupilumab Effectiveness in Biologic‐Naïve and Switched Severe Asthma in Real Life
por: Catherine Moermans, et al.
Publicado: (2025)

Comment on “Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis”
por: Kotina Shridevi, et al.
Publicado: (2026)

Protease Activity‐Independent, Th Cell‐Dependent Airway IL ‐33 Release Drives Eosinophilia in Mice Presensitized to Papain via SDS ‐Treated Skin
por: Keiko Takada, et al.
Publicado: (2026)

Real‐Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry
por: Robert Greig, et al.
Publicado: (2025)

Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis
por: Emeline Delaunay, et al.
Publicado: (2025)

Correspondence to ‘Interleukin‐5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils’
por: Christopher McCrae, et al.
Publicado: (2025)

Dichotomous STAT5 and STAT6 Activation in T Cells Reflects Cytokine Shifts Between Blood and Skin in Atopic Dermatitis
por: Andreas Boldt, et al.
Publicado: (2025)

Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response
por: Murat Türk, et al.
Publicado: (2025)

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
por: P. E. Vonk, et al.
Publicado: (2025)

Subcutaneous Allergen‐Specific Immunotherapy for Allergic Rhinitis: Divergent IgA Responses in Nasal Mucosa and Blood With Validation of B Cell Class‐Switching in Lymph Nodes and Blood
por: Maryam Jafari, et al.
Publicado: (2025)

Rethinking Blood Biomarkers in Autoimmune Urticaria: A Response to Recent Findings
por: Sukhdeep Singh, et al.
Publicado: (2024)

Large‐Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker Profiles
por: Jacob W. Glickman, et al.
Publicado: (2025)

Anaphylaxis Induced by Goat's and Sheep's Milk: An Allergen That We Should Keep Under Surveillance
por: Guillaume Pouessel, et al.
Publicado: (2025)

High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma
por: Lorenz Wirth, et al.
Publicado: (2025)

Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage
por: Eugenio De Corso, et al.
Publicado: (2025)

Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
por: Claus Bachert, et al.
Publicado: (2024)

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study
por: Sayantani B. Sindher, et al.
Publicado: (2024)

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study ( MAPS )
por: S. Preis, et al.
Publicado: (2026)

Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year
por: Josje J. Otten, et al.
Publicado: (2025)

Correction to “Higher Prevalence of Dupilumab‐Induced Ocular Adverse Events in Atopic Dermatitis Compared to Asthma: A Daily Practice Analysis”
Publicado: (2026)

Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes
por: Alessandra Vultaggio, et al.
Publicado: (2026)

Dupilumab Alleviates IL‐13‐Induced Nasal Epithelial Barrier Dysfunction by Regulating Claudin‐10 Expression
por: Zhi‐Qun Huang, et al.
Publicado: (2026)

Dupilumab efficacy by disease severity in pediatric type 2 asthma
por: Daniel J. Jackson, et al.
Publicado: (2025)

Identification of the Cytokines, Growth Factors and Their Receptors Expressed by Human Blood Eosinophils: A Transcriptomics Approach
por: Stephane Esnault, et al.
Publicado: (2025)

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region
por: Qingling Zhang, et al.
Publicado: (2025)